Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer, Clin Breast Cancer, vol.9, pp.73-81, 2009. ,
Deconstructing the molecular portraits of breast cancer, Mol Oncol, vol.5, pp.5-23, 2011. ,
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection, PloS One, vol.11, p.157368, 2016. ,
Molecular portraits of human breast tumours, Nature, vol.406, pp.747-752, 2000. ,
Metabotropic glutamate receptor-1 contributes to progression in triple negative breast cancer, PloS One, vol.9, p.81126, 2014. ,
Triple-negative breast cancer, N. Engl. J. Med, vol.363, pp.1938-1948, 2010. ,
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies, J. Clin. Invest, vol.121, pp.2750-2767, 2011. ,
Targeted therapy in breast cancer: what's new?, Swiss Med. Wkly, vol.141, p.13231, 2011. ,
Basal-like breast carcinoma: a phenotypically distinct entity, Arch. Pathol. Lab. Med, vol.134, pp.130-133, 2010. ,
Changing medium and passaging cell lines, Nat. Protoc, vol.2, pp.2276-2284, 2007. ,
Culture Conditions and Types of Growth Media for Mammalian Cells, 2012. ,
Serum-free cell culture: the serum-free media interactive online database, ALTEX, vol.27, pp.53-62, 2010. ,
Humanized' stem cell culture techniques: the animal serum controversy, Stem Cells Int, p.504723, 2011. ,
Long-term growth comparison studies of FBS and FBS alternatives in six head and neck cell lines, PloS One, vol.12, p.178960, 2017. ,
Spheroids Formation on Non-Adhesive Surfaces by Liquid Overlay Technique: Considerations and Practical Approaches, Biotechnol. J, 2017. ,
A three-dimensional collagen scaffold cell culture system for screening anti-glioma therapeutics, Oncotarget, vol.7, pp.56904-56914, 2016. ,
3D models of epithelial-mesenchymal transition in breast cancer metastasis: highthroughput screening assay development, validation, and pilot screen, J. Biomol. Screen, vol.16, pp.141-154, 2011. ,
3D tumor spheroids: an overview on the tools and techniques used for their analysis, Biotechnol. Adv, vol.34, pp.1427-1441, 2016. ,
3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtained, Sci. Rep, vol.6, 2016. ,
Development and cytotoxic response of two proliferative MDA-MB-231 and non-proliferative SUM1315 three-dimensional cell culture models of triple-negative basal-like breast cancer cell lines, Oncotarget, vol.8, pp.95316-95331, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01651313
Best practices for media selection for mammalian cells, In Vitro Cell. Dev. Biol. Anim, vol.53, pp.673-681, 2017. ,
Examining the sources of variability in cell culture media used for biopharmaceutical production, Biotechnol. Lett, 2017. ,
Animal-cell culture media: History, characteristics, and current issues, Reprod. Med. Biol, vol.16, pp.99-117, 2017. ,
Development of a Three-Dimensional Bioengineering Technology to Generate Lung Tissue for Personalized Disease Modeling, Stem Cells Transl. Med, vol.6, pp.622-633, 2017. ,
Deconstructing the molecular portraits of breast cancer, Mol. Oncol, vol.5, pp.5-23, 2011. ,
3D cell culture systems: advantages and applications, J. Cell. Physiol, vol.230, pp.16-26, 2015. ,
Matrigel: from discovery and ECM mimicry to assays and models for cancer research, Adv. Drug Deliv. Rev. 79, vol.80, pp.3-18, 2014. ,
Vimentin in cancer and its potential as a molecular target for cancer therapy, Cell. Mol. Life Sci. CMLS, vol.68, pp.3033-3046, 2011. ,
,
, D=KLJ9F< :J=9CK :Q L@= AF@A:ALAGF G> L@= "/ J=H9AJ KQKL=E L@MK <=?=F=J9LAF? AFLG !0K
,
,
,
, LAGF GF :GL@, vol.9, issue.9
,
,
, >GJ, vol.02
,
,
,
, , 2009.
,
, LAGF<=H=F<=FL OAL@ 9 J9LAG $Q >J9
,
,
,
,
,
,
,
,
, , vol.3, pp.9-9
, LAGF G> 9DD KLM<A=< H9J9E=L=JK 9F< 9 KLJGF? :=F=>AL LG HJGHGK= 9
,
,
, , 2009.
, , vol.9, 2009.
,
,
,
,
,
,
, , vol.9
, , pp.1-4
,
,
,
,
,
,
GL@ NA9:ADALQ 9F< ;DGFG?=FA; L=KLK @A?@DA?@L=< 9 ,
,
,
,
, =LL=J HJ=<A
,
, GDA; 9;LANALQ 9F< NA9:ADALQ EGJL9DALQ HJG>AD= G> *!* 9F<
, , vol.9, pp.9-9
,
,
,
,
,
,
,
,
,
, , vol.9
,
, , vol.9
,
ML L@= KH@=JGA< E=L9:GDA; 9, LANALQ <= ,
,
,
,
,
,
,
,
,
, , vol.9
,
,
, JGOL@K #-69)
,
,
,
, , vol.157
,
,
,
,
,
,
,
,
,
, , vol.9, pp.61-65
,
,
,
,
,
, 8C E8 #:8D'KD' &' 7:&)6/CD/:8 (, p.8
, 9#*3;)&97*$ '9
, , vol.7
, , p.8
8 )I/&'8#' 6'EB &/I'B-'8#'] 'DD' .)D)B:-)8)/D) -)8) ,
,
, B)C/CD8#' i@B:D)/8'C j :8D )D), vol.7
,
,
, , vol.2, p.0
, /CD/:8 @B)#6/8/AE' &' 6^#D/:8 &'C 7:6)#E6'C #
, /8D/DE6) a 6d b )D) &)I'6:@@) #:77'
,
, , vol.8
,
, , vol.452
Biology, metastatic patterns, and treatment of patients with triplenegative breast cancer, Clin. Breast Cancer, vol.9, issue.2, pp.73-81, 2009. ,
Three-dimensional cell culture: a breakthrough in vivo, Int. J. Mol. Sci, vol.16, pp.5517-5527, 2015. ,
Functional differentiation and alveolar morphogenesis of primary mammary cultures on reconstituted basement membrane, Dev. Camb. Engl, vol.105, pp.223-235, 1989. ,
Phenotypic and Molecular Characterization of MCF10DCIS and SUM Breast Cancer Cell Lines, Int. J. Breast Cancer, p.872743, 2013. ,
Goodbye flat biology -time for the 3rd and the 4th dimensions, J. Cell Sci, vol.130, pp.3-5, 2017. ,
Global estimates of cancer prevalence for 27 sites in the adult population in 2008, Int. J. Cancer, vol.132, pp.1133-1145, 2013. ,
The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance, Oncotarget, vol.7, pp.45745-45756, 2016. ,
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase, Nature, vol.434, pp.913-917, 2005. ,
Target engagement imaging of PARP inhibitors in small-cell lung cancer, Nat. Commun, vol.9, p.176, 2018. ,
Embedded multicellular spheroids as a biomimetic 3D cancer model for evaluating drug and drug-device combinations, Biomaterials, vol.35, pp.2264-2271, 2014. ,
3D tumor spheroids: an overview on the tools and techniques used for their analysis, Biotechnol. Adv, vol.34, pp.1427-1441, 2016. ,
Spheroids Formation on Non-Adhesive Surfaces by Liquid Overlay Technique: Considerations and Practical Approaches, Biotechnol. J, 2017. ,
Olaparib: first global approval, Drugs, vol.75, pp.231-240, 2015. ,
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first-or second-line treatment of patients with metastatic triple-negative breast cancer, Breast Cancer Res. BCR, vol.15, p.88, 2013. ,
Development and cytotoxic response of two proliferative MDA-MB-231 and nonproliferative SUM1315 three-dimensional cell culture models of triple-negative basal-like breast cancer cell lines, Oncotarget, vol.8, pp.95316-95331, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01651313
Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?, Curr. Oncol. Rep, vol.20, p.63, 2018. ,
Three-Dimensional Cell Cultures in Drug Discovery and Development, SLAS Discov. Adv. Life Sci. RD, vol.22, pp.456-472, 2017. ,
Targeted therapy in breast cancer: what's new?, Swiss Med. Wkly, vol.141, p.13231, 2011. ,
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, Nature, vol.434, pp.917-921, 2005. ,
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int. J. Cancer, vol.136, pp.359-386, 2015. ,
Triple-negative breast cancer, N. Engl. J. Med, vol.363, pp.1938-1948, 2010. ,
Pathways Involved in Formation of Mammary Organoid Architecture Have Keys to Understanding Drug Resistance and to Discovery of Druggable Targets, Cold Spring Harb. Symp. Quant. Biol, vol.81, pp.207-217, 2016. ,
Cancers de l'ovaire BRCA muté : consultation d'oncogénétique et prescription des inhibiteurs de PARP, Bull. Cancer (Paris), vol.104, pp.16-23, 2017. ,
, , 2014.
, PARPi-FL--a fluorescent PARP1 inhibitor for glioblastoma imaging, vol.16, pp.432-440
Optical Imaging of PARP1 in Response to Radiation in Oral Squamous Cell Carcinoma, PloS One, vol.11, p.147752, 2016. ,
Direct imaging of drug distribution and target engagement of the PARP inhibitor rucaparib, J. Nucl. Med. Off. Publ. Soc. Nucl. Med, 2018. ,
, , pp.11-11
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection, PloS One, vol.11, 2016. ,
Recent advances in three-dimensional multicellular spheroid culture for biomedical research, Biotechnol. J, vol.3, pp.1172-1184, 2008. ,
SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triplenegative breast cancer, Breast Cancer Res. Treat, vol.154, pp.351-357, 2015. ,
-ribose) polymerase-1, 2H-phthalazin-1-one: a novel bioavailable inhibitor of poly, vol.4, pp.6581-6591, 2008. ,
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes, Cancer Cell, vol.10, pp.515-527, 2006. ,
Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol, vol.23, issue.6, pp.19-22, 2012. ,
, Cancer Radiother. J. Soc. Francaise Radiother. Oncol, vol.18, pp.799-802, 2014.
, , 2012.
, Cancer Radiother. J. Soc. Francaise Radiother. Oncol, vol.16, pp.1-10
Imaging therapeutic PARP inhibition in vivo through bioorthogonally developed companion imaging agents, vol.14, pp.169-177, 2012. ,
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells, Br. J. Cancer, vol.88, pp.1285-1291, 2003. ,
Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer, Breast Cancer Res. Treat, 2018. ,
, , 2013.
, Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo, Nat. Commun, vol.4, p.1504
Effect of small-molecule modification on single-cell pharmacokinetics of PARP inhibitors, Mol. Cancer Ther, vol.13, pp.986-995, 2014. ,
Emerging therapeutic modalities of PARP inhibitors in breast cancer, Cancer Treat. Rev, vol.68, pp.62-68, 2018. ,
, &)B/I) ,6E:B'C#'8D &' 6^6@B/" a 6d b
,
, 8:D77'8D '8 @'B7'DD8D
,
&^)#.8D/66:8 #'66E6/B' 'D &^)D@'C &' &)D'#D/:8] uy| &6& ,
, Journal of PharmaceuticalReferences
Advances in PARP inhibitors for the treatment of breast cancer, Expert Opin. Pharmacother, vol.16, pp.2751-2758, 2015. ,
Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors From concept to clinic, J. Med. Chem, vol.53, pp.4561-4584, 2010. ,
Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited, Biochim. Biophys. Acta, vol.1846, pp.201-215, 2014. ,
Poly(ADP-ribose): novel functions for an old molecule, Nat. Rev. Mol. Cell Biol, vol.7, pp.517-528, 2006. ,
URL : https://hal.archives-ouvertes.fr/hal-00179861
PARP inhibitors: the race is on, Br. J. Cancer, vol.114, pp.713-715, 2016. ,
Trapping of PARP1 and PARP2 by clinical PARP inhibitors, Cancer Res, vol.72, pp.5588-5599, 2012. ,
PARP inhibitors: a new era of targeted therapy, Maturitas, vol.81, pp.5-9, 2015. ,
Predictors and modulators of synthetic lethality: an update on PARP inhibitors and personalized medicine, Biomed. Res. Int, p.2346585, 2016. ,
Olaparib: first global approval, Drugs, vol.75, pp.231-240, 2015. ,
Targeting the DNA damage response in cancer, Mol. Cell, vol.60, pp.547-560, 2015. ,
Intracellular drug concentrations, Clin. Pharmacol. Ther, vol.93, pp.263-266, 2013. ,
Mechanisms of resistance to PARP inhibitors-three and counting, Cancer Discov, vol.3, pp.20-23, 2013. ,
Mechanisms of resistance to therapies targeting BRCA-mutant cancers, Nat. Med, vol.19, pp.1381-1388, 2013. ,
BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib, Sci. Rep, vol.5, p.12670, 2015. ,
Thinking outside the bug: a unique assay to measure intracellular drug penetration in gram-negative bacteria, Anal. Chem, vol.87, pp.3579-3584, 2015. ,
Methods to measure the intracellular concentration of unlabeled compounds within cultured cells using liquid chromatography/tandem mass spectrometry, Anal. Biochem, vol.383, pp.186-193, 2008. ,
Rapid measurement of intracellular unbound drug concentrations, Mol. Pharm, vol.10, pp.2467-2478, 2013. ,
Improving the intracellular drug concentration in lung cancer treatment through the codelivery of doxorubicin and miR-519c mediated by porous PLGA microparticle, Mol. Pharm, vol.13, pp.3925-3933, 2016. ,
Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699), Pharm. Res, vol.32, pp.37-46, 2015. ,
Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying olaparib in human plasma, J. Chromatogr. B, vol.940, pp.121-125, 2013. ,
Liquid chromatography-tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma, J. Pharm. Biomed. Anal, vol.88, pp.626-629, 2014. ,
Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma, J. Chromatogr. B, vol.879, pp.1851-1856, 2011. ,
A sensitive and robust Ultra HPLC assay with tandem mass spectrometric detection for the quantitation of the PARP inhibitor olaparib (AZD2281) in human plasma for pharmacokinetic application, Chromatography, vol.1, pp.82-95, 2014. ,
Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment, ABBV Cell Cycle, vol.11, pp.3837-3850, 2012. ,
, Measurement of imatinib uptake by flow cytometry, vol.81, pp.996-1004, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00849687
Analysis of doxorubicin uptake in single human leukemia K562 cells using capillary electrophoresis coupled with laser-induced fluorescence detection, Anal. Bioanal. Chem, vol.401, pp.2143-2152, 2011. ,
Development and cytotoxic response of two proliferative MDA-MB-231 and non-proliferative SUM1315 three-dimensional cell culture models of triple-negative basal-like breast cancer cell lines, Oncotarget, vol.8, issue.56, pp.95316-95331, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01651313
, &3 42"6"58 'C DBIEK :8D @'B7/C 6 &)D'B7/8D/:8 &'C #:8&/D/:8C i/j &' @B)@BD/:8 &'C, vol.352
, , vol.6
, B6'CZ '8 #:BB)6D/:8 I'# 6'EB
,
,
,
, , p.8
, D)/8'C 74'EB'CZ, vol.6
, &EB8D vx.] 8C #' #:8D'KD'Z 8:EC I:8C :B/'8D) #'C DBIEK CEB 6 &)D'B7/8D/:8 &' 6 #:d 'K@B'CC/:8 &' 6
, G>: (DAQ8JA6>G: :I .IG6IQ<>:H /=QG6CDHI>FJ:H ! A:GBDCI !:GG6C9 !G6C8: $CHI>IJI 0C>K:GH>I6>G: 9: /:8=CDAD<>: QE6GI:B:CI "QC>: >DAD<>FJ: 0C>K:GH>IQ A:GBDCI JK:G<C: $)
, , vol.8
,
, 8JAIJG:9 >C 6C9 L>I= *A6E6G>7 IG:6IB:CI $C, vol.8
, , vol.2
, 6HI 86C8:G >H 6 K:GN 8DBEA:M 6C9 =:I:GD<:C:DJH 9>H:6H: BDC< I=: H:K, p.6
, +9 '2 #'8854+ +9 '2
, I=: E6I>:CIZH DJI8DB: H:K:G6A HE:8>;>8 I6G<:I:9 I=:G6E>:H HJ8= 6H +DAN + G>7DH: +DANB:G6H: >C=>7>IDGH +-+> :MEAD>I>C< I=: X-C:HH
,
, A6G<: E6C:A D; M:CD7>DI>8H EG>C8>E6AAN =N9GDE=D7>8 6C9 >DC>8 6BE=>E6I=>8 BDA:8JA:H HJ8= 6H 8=:BDI=:G6E:JI>8H .+4 +9 '2 599+83'4 +9, vol.6
,
,
, AA A>C: L6H 8JAIJG:9 >C #6B H ! B:9>JB ">78DS HJEEA:B:CI:9 L>I= 9, vol.8
, A>C:H 8:AAH L:G: H::9:9 >C BA D; 8JAIJG: B:9>JB 6I 6 8DC8:CIG6I>DC D, vol.8
, , vol.8
, AA A>C:H HE=:GD>9H ;DGB6I>DC I=: A>FJ>9 DK:GA6N I:8=C>FJ: L6H E:G;DGB:9 688DG9>C< ID EG:K>DJH LDG@H D; I=: I:6B :(5/8 +9 '2 :AAH L:G: H::9:9 >CID L:AA X0AIG6 'DL II68=B:CIY B>8GDEA6I:H DGC>C<S, vol.7
, 6<>I6IDG 6C9 I=:C >C8J76I, vol.8, p.9
,
, HID8@ HDAJI>DC *A6E6G>7 L6H I=:C 9>AJI:9 >C I=: 8JAIJG: B:9>JB 6I
, >C6A 8DC8:CIG6I>DCH D
, >C6A 8DC8:CIG6I>DC D; (.* >C I=: 8JAIJG: B:9>JB L6H D; :AAH 8JAIJG:9 >C BDCDA6N:G L:G: IG:6I:9 L>I= 6C9 V( *A6E6G>7
,
,
,
, >M:9 >C 8DA9 +6G6;DGB6A9:=N9: +! ;DG B>C L6H=:9 I=G:: I>B:H >C +. 6C9, vol.8, pp.9-15
,
, , pp.6-6
,
, , p.9
, , p.8
,
, AJDG:H8:C8: >B6<:G 6C9 I=: >B6<: 6C6ANH>H L6H E:G;DGB:9 L>I= $8NS HEDI 9, vol.9
,
, GD>9H L:G: L6H=:9 >C +. ;>M:9 L>I= +! 9
, , vol.6
, G:HE:8I>K:AN AA I=:H: G:HJAIH H=DL:9 I=6I I=: ADL 9DH: 6I ADC< I:GB *A6E6G>7 IG:6IB:CI >C9J8:9, vol.8, p.6
I:8I:9 6;I:G IG:6IB:CI "$ ,
,
,
,
, 69GN6B>8>C 8N8ADE=DHE=6B>9: EGDID8DAH 6HHD8>6I:9 L>I= I6M6C:H G:<>B:C *, p.29
,
, I=: E6I>:CIZH DJI8DB: H:K:G6A HE:8>;>8 I6G<:I:9 I=:G6E>:H HJ8= 6H +DAN + G>7DH: +DANB:G6H: >C=>7>IDGH +-+> :MEAD>I>C< I=: X-C:HH HI6IJHY D; IJBDJGH 7N I=: HNCI=:I>8 A:I=6A>IN 8DC8:EI L:G: 9:K:ADE:9 >C EG:8A>C>86A 6C9 8A>C>86A HIJ9>:H %'4-+9, vol.8
, AJDG:H8:CI 9:G>K6I>K: *A6E6G>7 BDA:8JA: *A6 !' =><=A><=I, pp.6-9
AA 8JAIJG:H /=, vol.8 ,
,
,
, ME:G>B:CIH E:G;DGB:9 >C 8:AA 8JAIJG: I=: H=DGI I:GB >C9J8I>DC D
, , p.9
,
, AJDG:H8:C8: >CI:CH>IN E:G 8:AA L6H 9:I:8I:9 6;I:G 6C9 V( G:HE:8I>K:AN $C 8DCIG6HI 6 ;DA9 >C8G:6H: >C + <E :MEG:HH>DC L6H 9:I:8I:9 DC I=>H, vol.8, p.9
,
, , vol.9
,
, :HH>DC L6H HIJ9>:9 6;I:G 6 ADC< I:GB 6C9 ADL 9DH: *A6E6G>7 IG:6IB:CI DC ( ( 6C9 .0( HE=:GD>9H $C9::9 DJG EG:K>DJH LDG@H, vol.9, p.9
, , vol.9, p.6
, , p.9
, ^86LC' &' 6 #:d'K@B'CC/:8 CEB 6'C #E6DEB'C v &' 6, vol.6
, EB 6 6/-8)' uwuyZ E#E8' 7:&/,/#D/:8 &' 6^'K@B'CC/:8 &' { 8^ )D) 7/C' '8 )I/&'8#' CE
, &8C 6'C 7*7'C #:8&/D/:8C 'K@)B/7'8D6'CZ &), p.4
,
,
, 6' &:C' &^6@B/"Z 6^'K@B'CC/:8 "C6' &' 6 { B'CD' /8#.8-)' 6:BC, DB/D'7'8D 6:8-dD'B7' I'# E8
,
,
,
,
,
, , 22379.
,
, @BD/#E6'C C:8D &' @6EC '8 @6EC &)I'6:@@)'C &8C 6' &:7/8' &' 6, vol.88
DZ 6'C 88:@BD/#E6'C &^:B a 8E'C b @B)C'8D'8D 6^/8D), vol.6 ,
, &E#D/:8 'D 6 #B#D)B/CD/:8 &' 88:@BD/#E6'C &^:B -L6)'C
, 9=<? 79&0*1*2*, p.32
,
,
Anthocyanin-Loaded PEG-Gold Nanoparticles Enhanced the Neuroprotection of Anthocyanins in an A? 1?42 Mouse Model of Alzheimer's Disease, Molecular neurobiology, vol.5, pp.1-17, 2016. ,
Nanomedicine Approaches in Vascular Disease: A Review. Nanomedicine: Nanotechnology, Biology and Medicine, p.7, 2011. ,
New Approach of Gold Nanoparticles for Treating Skin Disease, Journal of Dermatological Science, vol.8, 2016. ,
Gold Nanoparticles Based Imaging Technique and Drug Delivery for the Detection and Treatment of Atherosclerotic Vascular Disease, International Society for Optics and Photonics, p.9, 2016. ,
Recent Progress in Cancer Thermal Therapy Using Gold Nanoparticles, The Journal of Physical Chemistry C, vol.1, issue.120, pp.4691-4716, 2016. ,
,
Gold Nanoparticles for the Development of, Clinical Diagnosis Methods. Analytical and Bioanalytical Chemistry, vol.3, pp.943-950, 2008. ,
,
Early Diagnosis of Oral Cancer Based on the Surface Plasmon Resonance of Gold Nanoparticles, International Journal of Nanomedicine, vol.2, issue.2, p.785, 2007. ,
Nanoparticles for Multi-Modality Cancer Diagnosis: Simple Protocol for Self-Assembly of Gold Nanoclusters Mediated by Gadolinium Ions, Biomaterials, vol.1, issue.120, pp.103-114, 2017. ,
,
Surface-Enhanced Raman Spectroscopy of Blood Serum Based on Gold Nanoparticles for the Diagnosis of the Oral Squamous Cell Carcinoma, Lipids in Health and Disease, pp.1-16, 2017. ,
Light-Triggered Assembly of Gold Nanoparticles for Photothermal Therapy and Photoacoustic Imaging of Tumors in Vivo, Advanced Materials, vol.2, p.6, 2017. ,
, Silicone Rubber Films Func, 2017.
Acrylic Acid) Nanobrushes for Immobilization of Gold Nanoparticles and Photothermal Therapy, Journal of Biomaterials and Nanobiotechnology tionalized with Poly, vol.4, pp.245-254 ,
Theranostics Based on Iron Oxide and Gold Nanoparticles for Imaging-Guided Photothermal and Photodynamic Therapy of Cancer, Current Topics in Medicinal Chemistry, vol.1, pp.1858-1871, 2017. ,
,
Photothermal Therapy Using Folate Conjugated Gold Nanoparticles Enhances the Effects of 6MV X-Ray on Mouth Epidermal Carcinoma Cells, Journal of Photochemistry and Photobiology B: Biology, vol.1, pp.52-60, 2017. ,
,
Near-Infrared Photothermal Therapy Using EGFR-Targeted Gold Nanoparticles Increases Autophagic Cell Death in Breast Cancer, Journal of Photochemistry and Photobiology B: Biology, vol.1, pp.58-64, 2017. ,
,
The Assesment of Effectiveness of Plasmonic Resonance Photothermal Therapy in Tumor-Bearing Rats after Multiple Intravenous Administration of Gold Nanorods, International Society for Optics and Photonics, vol.1, issue.10336, p.103360, 2017. ,
, Dependence of Gold Nanoparticle Radiosensitization on Cell Geometry. Nanoscale, issue.9, 2017.
, , vol.9, pp.5843-5853
Biological Mechanisms of Gold Nanoparticle Radiosensitization, Cancer Nanotechnology, vol.8, 2017. ,
,
Increasing the Therapeutic Efficacy of Radiotherapy Using Nanoparticles, pp.241-265, 2017. ,
Hollow Gold Nanoparticles as Efficient in Vivo Radiosensitizing Agents for Radiation Therapy of, Breast Cancer. Journal of Biomedical Nanotechnology, issue.1, 2017. ,
, , vol.13, pp.566-574
Shape-Dependent Radiosensitization Effect of Gold Nanostructures in Cancer Radiotherapy: Comparison of Gold Nanoparticles, Nanospikes, and Nanorods, ACS Applied Materials & Interfaces, p.9, 2017. ,
,
Abstract B41: Gold Nanoparticles Based Platforms for Localized Radiosensitization in Cancer Radiation Therapy, Cancer Research, vol.7, 2017. ,
Targeted Dose Enhancement in Radiotherapy for Breast Cancer Using Gold Nanoparticles, Part 1: A Radiobiological Model Study, Medical Physics, vol.4, issue.44, 1983. ,
Gold Nanoparticles in Combination with Megavoltage Radiation Energy Increased Radiosensitization and Apoptosis in Colon Cancer HT-29 Cells, Journal of Biomaterials and Nanobiotechnology Arab-Bafrani, vol.9, pp.315-323, 2017. ,
,
Increased Radiotoxicity in Two Cancerous Cell Lines Irradiated by Low and High Energy Photons in the Presence of Thio-Glucose Bound Gold Nanoparticles, International Journal of Radiation Biology, vol.9, pp.407-415, 2017. ,
,
Angular Dose Anisotropy around Gold Nanoparticles Exposed to X-Rays, Nanomedicine: Nanotechnology, vol.1, pp.1653-1661, 2017. ,
,
Fabrication of Gold Nanoparticles for Targeted Therapy in Pancreatic Cancer, Advanced Drug Delivery Reviews, p.6, 2010. ,
, , vol.62, pp.346-361
Targeted Gold Nanoparticles Enable Molecular CT Imaging of Cancer: An in Vivo Study, International Journal of Nanomedicine, p.6, 2011. ,
The Use of Gold Nanoparticles to Enhance Radiotherapy in Mice, Physics in Medicine and Biology, vol.4, p.49, 2004. ,
Increased Apoptotic Potential and Dose-Enhancing Effect of Gold Nanoparticles in Combination with Single-Dose Clinical Electron Beams on Tumor-Bearing Mice, Cancer Science, vol.9, pp.1479-1484, 2008. ,
,
Laser-Induced Explosion of Gold Nanoparticles: Potential Role for Nanophotothermolysis of Cancer, Nanomedicine, 1, vol.1, pp.473-480, 2006. ,
Computationally Guided Photothermal Tumor Therapy Using Long-Circulating Gold Nanorod Antennas, Cancer Research, vol.6, pp.3892-3900, 2009. ,
,
Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer, Clinical Breast Cancer, vol.9, pp.73-81, 2009. ,
,
Deconstructing the Molecular Portraits of Breast Cancer, Molecular Oncology, vol.5, pp.5-23, 2011. ,
Metabotropic Glutamate Receptor-1 Contributes to Progression in Triple Negative Breast Cancer, PLoS ONE, vol.9, 2014. ,
Targeted Therapy for Triple-Negative Breast Cancer: Where Are We?, International Journal of Cancer, vol.1, pp.2471-2477, 2012. ,
,
, , 2015.
25 Journal of Biomaterials and Nanobiotechnology pression in Triple Negative Basal-Like Breast Cancer Cell Line: A Prospective Role in Resistance to, Olaparib. Scientific Reports, p.5 ,
,
Anti-EGFR Monoclonal Antibodies Enhance Sensitivity to DNA-Damaging Agents in BRCA1-Mutated and PTEN-Wild-Type Triple-Negative Breast Cancer Cells, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01671367
, Molecular Carcinogenesis, vol.5, pp.1383-1394
Anti-EGFR Monoclonal Antibodies and EGFR Tyrosine Kinase Inhibitors as Combination Therapy for Triple-Negative Breast Cancer, Oncotarget, vol.7, pp.73618-73637, 2016. ,
AZD-2281, in Combination with Fractionated Radiotherapy: An Exploration of the Therapeutic Ratio, Vivo Studies of the PARP Inhibitor, vol.1, pp.486-494, 2015. ,
,
Gold Nanoparticles in Breast Cancer Treatment: Promise and Potential Pitfalls, Cancer Letters, vol.3, pp.46-53, 2014. ,
,
Development and Cytotoxic Response of Two Proliferative MDA-MB-231 and Non-Proliferative SUM1315 ThreeDimensional Cell Culture Models of Triple-Negative Basal-Like Breast Cancer Cell Lines, Oncotarget, vol.8, pp.95316-95331, 2017. ,
, KALADRUG-R: Laboratory SOP#18. Simple Method and Tool for Calculation IC50-Values, 2010.
PEGylation, Successful Approach to Drug Delivery, Drug Discovery Today, p.1, 2005. ,
, , pp.3575-3575
Nanoparticle PEGylation for Imaging and Therapy, Nanomedicine, p.6, 2011. ,
,
Folic Acid Conjugated PEG Coated Gold-Iron Oxide Core-Shell Nanocomplex as a Potential Agent for Targeted Photothermal Therapy of Cancer, Nanomedicine, and Biotechnology, pp.1-11, 2017. ,
,
Multibranched Gold Nanoparticles with Intrinsic LAT-1 Targeting Capabilities for Selective Photothermal Therapy of Breast Cancer, ACS Applied Materials & Interfaces, p.9, 2017. ,
,
Size-Dependent Localization and Penetration of Ultrasmall Gold Nanoparticles in Cancer Cells, Multicellular Spheroids, and Tumors in Vivo, ACS Nano, p.6, 2012. ,
, , pp.4483-4493
C CEB 6 6/-8)' \d^b, C )DE&'C #:7@6)7'8D, vol.88, p.8 ,
, CEB 6' &)I'6:@@'7'8D &'C, vol.7
,
,
,
@B:6/,)BD/,C] '@'8&8DZ 6'C 7:6)#E6'C #LD:CDD/AE'C 8' @'EI'8D *DB, vol.7, p.77 ,
, :2&'C @@B1D #:77' E8' )D@' @B
, &)I'6:@@'7'8D &'C #E6DEB'C '8 w )-6'7'8D )D) B)6/C)Z &8C 6
, @B)C'8D/'8D )-6'7'8D E8 @B
,
,
, C8D 6 7*7' 7)D.:&:6:-/' @B)#)&'77'8D &)I'6:@@)'Z ivj &' B)D"6/CC'7'8D &E @B:,/6 @B:6/,)BD/, &'C C@.)B:2&'C /CCEC &' 6, vol.6
, C w I/CddI/C &'C 7:6)#E6'C, vol.6
, 'C C:8D #DE'66'7'8D '8 #:EBC &' &)I'6:@@'7'8D, vol.7
, 8C E8 &'EK/(7' D'7@CZ 6'C 7:&(6'C &' C@.)B:2&'C /8C/ &)I'6:@@)C :8D )D)
6' 'D &' CEBI/' #6:8:-)8/AE' B)6/C)C &8C E8 @B'7/'B D'7@C CEB 6'C 6/-8)'C #'66E6/B'C uwuy 'D ,
, :77' )D8D &)@'8&8D' iuj &' 6 &:C' &' B&/:D.)B@/' 'D ivj &' 6 &EB, p.8
, @B)C'8#' &' &:C'C B'6D/I'7'8D
,
CZ 6'C 'K@)B/'8#'C CEB 6'C #E6DEB'C w :8D )D) B)6/C)'C '8 @B)C'8#' &^E8' ,:BD' &:C' iyt j 'D &^E8 ,
, /D/:8 &' #B:/CC8#' 'D 6^/8&E#D/:8 &' 6 7:BD6/D) &'C #'66E6'C, p.78
,
8D 7/C '8 )I/&'8#' E8' "C'8#' &' ")8),/#' DB/D'B 6'C C@.)B:2&'C, p.88 ,
, )B@/' ,B#D/:88)'Z E8' .)D)B:-)8)/D) &' B)@:8C' '8DB' 6'C &'EK 6/-8)'C #'66E6/B'C )DE&/)'C
, , p.88
, , p.8
, BD #6/8/AE' &' #'DD' 7)D.:&:6:-/' &' #
, /8/B 6 &:C' &^6@B/" 7K/76' D:6)B)
, $ 0*, vol.31
, , 2009.
, , vol.9
,
,
, ' :8D @:BD) CEB 6' &)I'6:@@'7'8D
, 'C &' C@.)B:2&'C ] ' 7BAE'EB ,6E:B'C#'8D 6d &8C E8 @B'7, vol.7
, , p.8
#:8,/B7'B 6 B@/&' @)8)DBD/:8 'D 6 ,
C )DE&/)'C i d dvwuZ uwuy 'D u}w{j] 8CE/D'Z 6^86LC' &' 6 @)8)DBD ,
, &^/8#E"D/:8 @'B7/C &' &)7:8D'B iuj E8' @)8)DBD/:8 B@/&' &' 6^6d &8C 6^/8D)-B6/D)
D)B:-)8)/D) #'66E6/B' iC@.)B:2&'C -)C &' @6EC & ,
,
,
C DBIEK :8D )D) B)6/C)C CEB 6'C 6/-8)'C #'66E6/B'C ,
C @6EC 6:8-dD'B7'Z @B, vol.7 ,
,
, DZ E8' /8&E#D/:8 &^'K@B'CC/:8 &' 6 d-@ E &)@'8& &' 6 { )D) &)D'#D) '8 @B)C'8#'
, EB 6 6/-8)' uwuyZ E#E8' /8&E#D/:8 &' 6 @:7@' { 8^ )D) /&'8D
,
, I/'8D &)4 &)7:8DB) E8' #:d'K@B'CC
D/:8 'D '8 @B)C'8#' &' yt &^6@B ,
, C B)CE6DDC 7:8DB'8D 8:8 C'E6'7'8D 6^'K@B'CC
C 'K@)B/'8#'C &^86LC'C &' 6^#D/I/D) &' #'C '8 @B)C'8#, 6'7'8DZ 6' B<6' B'6'I8D &' 6 ,
,
,
,
,
,
,
#:66":BD/:8 &' DL@' @E"6/#c@B/I) I'# &'EK @BD'8/B'C /8&ECDB/'6CZ 6 ,
, BD/:8 6' @B:4'D ^ Z &:D) &^E8 ,/88#'7'8D &'C ,:8&C 'EB:@)'8C, p.66
, 6E/d#/Z &^E8' &EB)' 'CD
, , p.750
, )#E6'C '8 &)I'6:@@'7'8D
, /8&ECDB/'66'C /8#6E'8D iuj 6' &)I'6:@@'7'8D 'D 6 #B#D)B/CD/:8 &'C 7:&(6'C w '8 #:d#E6DEB'C iI'# &'C #'66E6'C
, D'8/B &'C 7:&(6'C '8#:B' @6EC @B)&/#D/,C &' 6 B)@:8C' DE7:B6' (
,
, , vol.7
,
, BD:/B' '8 #:77E8 i@B:4'D &' j] vtv ! vtw ? &I8/Z ::4Z 'D 6IB: :B'8
, !67 /!5 M 09! ! (-5!66N z\ y} {u
,
,
, D/:8d&'Cd#:7@B/7'Cd 6L8@BMddd:6@B/"dd@:EBd6'dDB/D'7'8].D76] ? a @@B:I'& BE-C d @@B:I'C 6@B
, Ic BE-Cc8,:B7D/:88 BE-Cc @@B:I'& BE-CcE#7y}vwy{
,
,
,
,
,
, @D5' 8& ,6EK :, :6L#L#6/# B:7D/# L&B:#B":8C "L 'DB.L7'8 LB
,
, , vol.56
DD@C\cc&:/]:B-cut]utw|cCB'@vyu|{] ? '8D:8Z "B/'6Z B/8 B8:ED:IZ L ':B-'Z L8& ] 6'/878Z 'D '88, 6\ B:7 /C#:I'BL 8& /7/#BL D: CCLC 8& :&'6C ,:B 8#'B 'C'B#. b] 9/! 58& !-(9!5< !9 ,
,
, , vol.8
,
,
,
,
,
, 7CZ L8 ] B5'BZ 8 6:J'BZ 6'8 :@'MZ EM88' L6'Z B5 'ED
,
, / %05 /!5 !6!5' uw i|j\ vwv} wx, vol.53
, DD@C\cc&:/]:B-cut]uuxzc88EB'Id @.B7D:Kdtuuzuwduwy}y}] ? :77/CC/:8'BZ
, , p.6
,
, ' 085/-0% /!5 uuu ixj\ z}z {t{, vol.6
/8 B/@6' '-D/I' C6d6/5' B'CD 8#'B '66 /8'\ B:C@'#D/I' :6' ,
, B:I'BZ /dC/8 8Z :8-#
, 8Z B)&)B/AE' ', vol.8, p.0
JC5/Z I'Cd'8 /-8:8Z B)&)B/AE ,
, , vol.6
, B@L i jd /8-6'd '8D'B B:C@'#D/I' 8&:7/M'& B/6 b] !850685&!5< |w iwj\ yzz {w
, DD@C\cc&:/]:B-cut]utw|c8DEB'twxxy] ? 'B6LZ #AE'CZ C"'66' :'B4:7DB7Z 4'C. /5C./DZ E6D8 C'BZ :6/8 D
, , vol.8
,
, 8D'B8D/:86 K@'BD :8C'8CEC :8 D.' B/7BL .'B@L :, B6L B'CD 8#'B vtuu b
,
,
,
,
, 667B5C :, 8#'B b] !--utt iuj\ y{ {t] ? 8"LZ
,
,
, EC'BZ B8M/C5Z '/5' '88'Z 6E&/ /DD,'6&Z :8D.8 'CDZ :6,-8-E'66'Bd6
,
,
,
,
, , vol.8
,
, /!5 ww iyj\ vvw wt
, /C5 #D:BC] 8#:DL@' CCL B'&/#DC :#6 '#EBB'8#' /8 B'CD 8#'B b] 785! !9
,
CC'88'Z 6/B' AE'DZ '8d/'BB' EB'CZ D./6&' Ld '66/6'Z 'D I'Cd ,
,
CC/:88'6CdB'#.'B#.'cB'#.'B#.'d@B'd#6/8/AE'c'K@'B/7'8DD/:8d8/76'cB'-6'd wdBdB'&E/B'dB ,
,
,
,
, /!5 !77!56 wx{ iuj\ xz yw
, /D:BC ,:B ucv EDD/:8d CC:#/D'& 8& d6/5' 6/-88#
,
,
, , vol.7
,
,
,
,
,
,
, DD@C\cc&:/]:B-cut]utw|c8B#u|}w] ? ::Z B#Ld 88Z #, 6F /!5 z i|j\ y|w }v, vol.6
66' '8&'BC:8Z /#.'66 ,
,
,
,
,
, , vol.66
, B7D/:88 BE-Cc @@B:I'&
, Ic BE-Cc8,:B7D/:88 BE-Cc @@B:I'& BE-CcE#7y}vwy{
,
,
, , pp.0-0
,
B&] vttv] a B'CD 8#'B B'D7'8D i pj\, vol.6 ,
,
, 6:-/#6 8& :6'#E6B
, 66#5Z 'D 6] vttt] a :6'#E6B :BDB/DC :, E78 B'CD E7:EBC b] 785! xtz iz{}{j\ {x{ yv
,
,
, , vol.6
,
, 6' CDB8& "B'5 B'@/BZ :8' 7'#.8/C7 #8 ./&' 8:D.'B\ 6D'B8D/I' 8:8d.:7:6:-:EC '8&, vol.4
,
, !/! M!: 05,D FFN w i{vj\ {vz v}
,
, E78 E6D/&BE-'C/CD8#' 8&, vol.8
,
,
,
,
,
,
,
,
,
,
,
D'I'8 ] 66'8Z EdCE5' :B/CJZ /D#, vol.66 ,
,
,
, /8/'6Z .8D6 EBLZ 'B-' '66/'BZ I
,
,
,
, 8Z 7'6/8'Z I8 JBML8/5Z .B/CD/8 7"6B&Z, vol.8
,
,
,
,
,
,
,
,
,
,
,
,
,
, %#4#%6>4+5>'5 2#4 70' #$5'0%' &G':24'55+10 &'5 4>%'26'745 #7: F5641)?0'5 = .# 241)'56>410' .G#$5'0%' &, vol.5, p.5106
, 06*>6+37' .'5 #06+ 5 %+$.'06 .'5 24124+>6>5 &'5 67/'745 #05 %' %106':6' %'5 64#8#7: &' 4'%*'4%*' 106 >6> 14+'06>5 574
,
, 06*>6+37' +06+67.> #05 70
,
, >4#06 510 14+)+0' />6#56#6+37' %>4>$4#
,
, * &G+0%7$#6+10  6176
,
, 10) 6'4/' 70' ':24'55+10 $#5#
, 5>47/ #06+ .#2#4+$ 4#&+16*>4#2+' (4#%6+100>' %1/$+0>' 7.6+47) '5+56#0%' )
,
,
, *+)* &15'5 #0&
, #0& ! %7.674'& +0 #0& %10&+6+105 *'5
+0'5 5*19'& # *'6'41)'0'175 5'05+6+8+6; 61 6*' %1 64 ,
,
, 6#56#6+% 14+)+0 *'5' 241/+5+0) 4'57.65 %17, '56+0) +65 %'4'$4#
,
, 56 +65 )4', vol.57
, , vol.6